Key Insights

Highlights

Treatment Research

2 treatments under study, led by Kzr261

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
Phase 1 (2)

Trial Status

Terminated1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07878988Phase 1Recruiting

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

NCT05047536Phase 1TerminatedPrimary

KZR-261 in Subjects With Advanced Solid Malignancies

Showing all 2 trials

Research Network

Common Treatments

  • Kzr2611
  • Ltz2321

Active Sponsors

  • Kezar Life Sciences, Inc.1
  • LTZ Therapeutics, Inc.1

Related Conditions

  • Colon Cancer1
  • Colorectal Cancer1
  • Epcam1
  • Solid Tumor Phase I1

Activity Timeline